The proposal marks another major milestone for the advanced cancer treatment and could be a windfall for hospitals.
Gilead Sciences is accused of giving kickbacks to healthcare organizations, government agencies, universities and community groups to boost sales of its hepatitis and HIV drugs, resulting in billions of dollars in excess government spending.
Alex Azar blasted the insurer practice of having a patient start over on step therapy if they switch insurance plans, as HHS aims to apply step therapy to Medicare Part B and D.
The latest and greatest health IT innovations will be on display among the nearly 1,200 vendors. Top level HHS officials, including Alex Azar, Seema Verma and Dr. Donald Rucker, are scheduled to speak.
The proposal led by Rep. Lloyd Doggett (D-Texas) and Sen. Sherrod Brown (D-Ohio) would let the government override patents if manufacturers don't play ball on drug prices for Part D.
House and Senate lawmakers reintroduced the Creates Act, a controversial bill aimed at curbing tactics brand-name drugmakers use to stymie generic and biosimilar competition.
Highmark Health CFO Karen Hanlon says the integrated delivery system is focused on expanding some of its value-based initiatives.
After HHS proposed eliminating the safe harbor protection for Medicare Part D drug rebates, Secretary Alex Azar suggested commercial plans will also get rid of the rebates in order to align with the market.
Drug distributor McKesson Corp. says it expects to shoulder more than $100 million in opioid-related legal expenses this year. Both McKesson and AmerisourceBergen downplayed their roles in the opioid epidemic in their respective earnings calls.
Under the proposal, price reductions offered by drugmakers to PBMs, Medicare Part D and managed care plans would not receive safe harbor protection as "discounts." Those rebates could be subject to prosecution under the Anti-Kickback Statute.
John Kapoor, the wealthy founder of drugmaker Insys Therapeutics plotted to bribe doctors across the country to prescribe a highly addictive fentanyl spray in order to outshine competitors and line his own pockets, a federal prosecutor told jurors Monday.
Buckle up, Big Pharma, it's going to be a bumpy ride in Congress this year. Senate Finance Committee Chair Chuck Grassley will gavel in the first of a series of hearings on soaring drug prices.